| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Velan Capital Investment Management LP | 9.6% | $7,578,242 | 2,668,395 | Velan Capital Investment Management LP | 19 Sep 2025 | |||
| T. Rowe Price Investment Management, Inc. | 7.1% | $4,897,117 | 2,057,612 | T. Rowe Price Investment Management, Inc. | 30 Sep 2025 | |||
| ACORN BIOVENTURES, L.P. | 6.4% | $4,162,526 | 1,786,492 | Anders Hove | 01 Dec 2025 | |||
| Soleus Capital Master Fund, L.P. | 10% | $5,409,800 | 1,494,420 | Soleus Capital Management, L.P. | 31 Dec 2024 | |||
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 4.7% | -8% | $3,153,131 | +$1,332,431 | 1,324,845 | +73% | Kingdon Capital Management, L.L.C. | 30 Sep 2025 |
| Qiming U.S. Healthcare Fund II, L.P. | 3.3% | $2,210,934 | 928,964 | Qiming U.S. Healthcare Fund II, L.P. | 30 Sep 2025 | |||
| MORGAN STANLEY | 2.8% | -44% | $1,867,415 | +$62,296 | 784,628 | +3.5% | Morgan Stanley | 30 Sep 2025 |
| BlackRock, Inc. | 1.5% | $1,019,735 | 225,605 | BlackRock, Inc. | 30 Jun 2025 |
As of 30 Sep 2025, 60 institutional investors reported holding 20,155,606 shares of Jasper Therapeutics, Inc. - Common Stock, $0.001 Par Value (JSPR). This represents 72% of the company’s total 27,913,938 outstanding shares.
The largest institutional shareholders of Jasper Therapeutics, Inc. - Common Stock, $0.001 Par Value (JSPR) together control 70% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Velan Capital Investment Management LP | 9.6% | 2,668,395 | +86% | 5.8% | $6,205,880 |
| Soleus Capital Management, L.P. | 5.4% | 1,494,420 | 0% | 0.19% | $3,556,720 |
| ACORN CAPITAL ADVISORS, LLC | 5% | 1,382,640 | 1.7% | $3,290,683 | |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 4.7% | 1,324,845 | +93% | 0.49% | $3,153,131 |
| Rock Springs Capital Management LP | 3.9% | 1,100,726 | +102% | 0.15% | $2,619,728 |
| Carlyle Group Inc. | 3.8% | 1,066,189 | 0% | 0.06% | $2,526,868 |
| Woodline Partners LP | 3.7% | 1,039,751 | 0.01% | $2,474,607 | |
| VANGUARD GROUP INC | 3.7% | 1,032,842 | +65% | 0% | $2,458,164 |
| T. Rowe Price Investment Management, Inc. | 3.7% | 1,028,806 | +46% | 0% | $2,449,000 |
| Propel Bio Management, LLC | 3.7% | 1,028,806 | 2.5% | $2,448,558 | |
| QIMING U.S. VENTURES MANAGEMENT, LLC | 3.3% | 928,964 | 0% | 4% | $2,210,934 |
| MORGAN STANLEY | 2.8% | 789,960 | +2.6% | 0% | $1,880,105 |
| SPHERA FUNDS MANAGEMENT LTD. | 2.3% | 629,470 | +4191% | 0.36% | $1,498,139 |
| Simplify Asset Management Inc. | 2.2% | 609,053 | 0.03% | $1,449,546 | |
| CITADEL ADVISORS LLC | 2.1% | 589,449 | +44% | 0% | $1,402,889 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.6% | 442,642 | 0.03% | $1,053,488 | |
| Lion Point Capital, LP | 1.4% | 398,558 | +172% | 5.4% | $948,568 |
| MILLENNIUM MANAGEMENT LLC | 1.3% | 364,939 | +151% | 0% | $868,555 |
| ARMISTICE CAPITAL, LLC | 1.2% | 348,000 | 0.03% | $828,240 | |
| BANK OF AMERICA CORP /DE/ | 1.1% | 294,553 | +0.37% | 0% | $701,036 |
| RENAISSANCE TECHNOLOGIES LLC | 0.75% | 208,500 | +1905% | 0% | $496,230 |
| BlackRock, Inc. | 0.73% | 204,932 | -9.2% | 0% | $487,738 |
| Knott David M Jr | 0.61% | 171,389 | 0.17% | $407,906 | |
| DEUTSCHE BANK AG\ | 0.57% | 160,000 | 0% | 0% | $380,800 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.47% | 130,855 | -0.21% | 0% | $311,559 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$7,378 | $1.79 | 0 |
| 2025 Q3 | 20,155,606 | $47,815,876 | +$13,373,881 | $2.38 | 60 |
| 2025 Q2 | 12,514,434 | $69,456,410 | -$2,535,021 | $5.55 | 63 |
| 2025 Q1 | 13,034,173 | $56,047,403 | -$70,633,611 | $4.30 | 66 |
| 2024 Q4 | 15,646,434 | $334,366,183 | +$15,008,655 | $21.38 | 84 |
| 2024 Q3 | 14,676,954 | $274,621,162 | -$5,485,863 | $18.81 | 77 |
| 2024 Q2 | 14,557,013 | $329,580,336 | +$34,892,996 | $22.70 | 68 |
| 2024 Q1 | 12,950,959 | $379,146,145 | +$359,441,971 | $29.36 | 56 |
| 2023 Q4 | 494,706 | $390,323 | +$390,323 | $0.79 | 1 |